HK Stock Market Move | JD Health (06618) opened over 3% higher after the performance report, with the annual net profit attributable to shareholders increasing by 29.16% year-on-year. The closed-loop system of "medical examination, diagnosis, and medication" has been further improved.

JD HEALTH (06618) opened more than 3% higher after the performance, rising 3.58% as of press time, reporting 49.2 Hong Kong dollars with a turnover of 1707.67 million Hong Kong dollars. On the news front, on March 5th, JD HEALTH released its annual results for the year ended December 31, 2025. The group achieved revenue of 73.441 billion yuan (RMB, same below), an increase of 26.3% year-on-year; the Company's owner's share of profit was 5.375 billion yuan, an increase of 29.16% year-on-year; basic earnings per share were 1.7 yuan. During the reporting period, JD HEALTH's advantage in "The first stop of new drugs online release" further expanded, with over 100 new drugs released throughout the year, a significant increase from 2024, fully reflecting JD HEALTH's core competitive strength in efficient pharmaceutical supply chain system and professional service capabilities. In 2025, JD HEALTH further improved the "medical-examination-diagnosis-medicine" service loop, continued to consolidate the integrated medical and health service capabilities of Wuxi Online Offline Communication Information Technology Co., Ltd., JD Internet Hospital continued to strengthen the construction of special capabilities in dermatology, psychology, chronic diseases, etc., JD Daojia's quick inspection service has expanded to 27 cities across the country, providing users with more than 160 home inspection services; at the same time, JD HEALTH also relies on AI technology to optimize the product usage experience of intelligent consultation and health management, improve service accuracy and accessibility, and build a professional and efficient full-scene health service system.